AL
Albert David Ltd (ALBERTDAVD)
₹762.60
Mkt cap
₹445 Cr
P/E ratio
15.50
P/B
1.03
Div yield
0.64%
ROE
−0.44%
ROCE
0.82%
EPS (TTM)
₹49.20
Book value
₹739
52W range
580–932
Sector
Healthcare
Price history
Previous close
Incorporated in 1938, Albert David Ltd is in the business of manufacturing pharmaceutical products [1]
NSE ALBERTDAVDBSE 524075
Health check
Cautious
ValuationCheap
ProfitabilityWeak
GrowthLow
TechnicalsNeutral
52-week range
−18.16% from high₹763
₹580+31.51% from low₹932
Current
₹762.60
Prev close
₹755.35
Day
+0.96%
Price performance
1D
+1.81%
1W
−2.04%
1M
−1.95%
3M
−10.91%
6M
+8.88%
1Y
−5.49%
YTD
+1.32%
Financials
Revenue, profit & margin
P/E ratio
15.5×
ALBERTDAVD is 54% below the sector median of 33.4×
ALBERTDAVD15.5×
Sector median33.4×
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 93.18 | 88.28 | 89.06 | 89.36 | 98.44 | 83.08 | 74.89 | 70.57 | 87.24 | 89.93 | 85.86 | 101.34 | 100.83 | |
| YoY Sales growth | +0.87% | +18.39% | +9.38% | -2.82% | +5.64% | -5.89% | -15.91% | -21.03% | -11.38% | +8.25% | +14.65% | +43.60% | +15.58% | |
| Expenses | 77.21 | 79.92 | 79.49 | 88.48 | 92.22 | 82.40 | 79.64 | 81.23 | 84.70 | 79.10 | 83.10 | 90.70 | 89.18 | |
| Operating Profit | 15.97 | 8.36 | 9.57 | 0.88 | 6.22 | 0.68 | -4.75 | -10.66 | 2.54 | 10.83 | 2.76 | 10.64 | 11.65 | |
| OPM % | 17.14% | 9.47% | 10.75% | 0.98% | 6.32% | 0.82% | -6.34% | -15.11% | 2.91% | 12.04% | 3.21% | 10.50% | 11.55% | |
| Other Income | 12.10 | 16.88 | 10.44 | 23.06 | 20.64 | -9.01 | -5.11 | 22.04 | -2.14 | 12.40 | -24.84 | 27.96 | -3.64 | |
| Interest | 0.06 | 0.12 | 0.07 | 0.09 | 0.06 | 0.13 | 0.13 | 0.55 | 0.75 | 0.90 | 0.43 | 0.52 | 0.40 | |
| Depreciation | 1.46 | 1.68 | 1.83 | 1.79 | 1.67 | 1.70 | 1.82 | 2.39 | 2.23 | 2.42 | 2.72 | 2.29 | 2.52 | |
| Profit before tax | 26.55 | 23.44 | 18.11 | 22.06 | 25.13 | -10.16 | -11.81 | 8.44 | -2.58 | 19.91 | -25.23 | 35.79 | 5.09 | |
| Tax % | 23.54% | 20.14% | 28.77% | 14.60% | 28.09% | -7.68% | -12.53% | 5.92% | 27.91% | 23.10% | -15.06% | 10.62% | 43.42% | |
| Net Profit | 20.30 | 18.72 | 12.91 | 18.84 | 18.07 | -9.39 | -10.33 | 7.94 | -3.30 | 15.30 | -21.43 | 32.00 | 2.88 | |
| EPS in Rs | 35.57 | 32.80 | 22.62 | 33.01 | 31.66 | -16.45 | -18.10 | 13.91 | -5.78 | 26.81 | -37.55 | 56.07 | 5.05 | |
| Raw PDF |
Earnings
Results dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Corporate actions
Last 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Shareholding
as of Sep 202662.23%Promoter
Promoters62.23%
FIIs0.60%0.03
DIIs1.63%
Public35.53%0.03
Ownership trend
Peers
8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | ₹1,867.50 | 36.42 | 4,48,076 | 0.86% | 1,995 | −10.53% | 16,199 | +11.88% | 20.53% |
| Divi's Lab. | ₹11,080.00 | 86.07 | 2,94,139 | 0.27% | 1,127 | +63.57% | 3,676 | +35.40% | 21.97% |
| Torrent Pharma. | ₹4,691.20 | 82.19 | 1,78,438 | 0.81% | 534 | −10.03% | 4,979 | +50.79% | 15.19% |
| Laurus Labs | ₹2,220.00 | 89.52 | 1,19,949 | 0.09% | 436 | +126.43% | 2,206 | +33.44% | 17.76% |
| Zydus Lifesci. | ₹1,192.00 | 26.24 | 1,18,902 | 0.08% | 928 | −27.96% | 7,910 | +29.17% | 21.14% |
| Dr Reddy's Labs | ₹1,377.90 | 41.11 | 1,15,092 | 0.58% | 913 | −31.35% | 8,698 | −1.48% | 13.04% |
| Cipla | ₹1,394.50 | 36.28 | 1,12,660 | 0.93% | 852 | −35.05% | 7,404 | −2.44% | 15.49% |
| Albert David | ₹778.90 | 15.47 | 445 | 0.64% | 3 | +187.27% | 101 | +15.58% | 0.82% |
| Median: 160 Co. | ₹449.50 | 33.40 | 2,018 | 0.08% | 13 | +33.73% | 179 | +21.23% | 14.94% |
Filings
Annual reports15
Credit ratings6
Announcements5
Announcement under Regulation 30 (LODR)-Newspaper Publication 13 Nov - Newspaper Publication-Regarding Extract of Unaudited Financial Results for the quarter and half year ended 30th September, 2026Unaudited Financial Results For The Quarter And Half Year Ended 30Th September, 2026 12 Nov - Board approved unaudited Q2 and half-year FY2026 results on November 12, 2026.Board Meeting Outcome for Outcome Of Board Meeting Related To Approval Of Unaudited Financial Results For The Quarter And Half Year Ended 30Th September, 2026 12 Nov - Board approved unaudited Q2 and half-year FY2026 financial results on November 12, 2026.Board Meeting Intimation for Intimation Of Board Meeting Under Regulation 29 Of SEBI Listing Regulations 29 Oct - Board meets November 12, 2026 to approve Q2 and half-year FY27 unaudited results.Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 6 Oct - Submitted Regulation 74(5) compliance certificate for July 1-September 30, 2026.






